Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer

Oncologist

Volumn 13, Issue 4, 2008, Pages 361-369

  Ardavanis, Alexandros ^a   Kountourakis, Panteleimon ^a   Kyriakou, Flora ^a   Malliou, Savoula ^a   Mantzaris, Ioannis ^a   Garoufali, Anastasia ^a   Yiotis, Ioulia ^a   Scorilas, Andreas ^b   Baziotis, Nikolaos ^a   Rigatos, Gerasimos ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anthracycline taxane resistant; HER 2 ECD; HER 2 neu; Metastatic breast cancer; Salvage

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CAPECITABINE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GROWTH; CONSTIPATION; DIARRHEA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ONCOGENE NEU; OVERALL SURVIVAL; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; REFRACTORY PERIOD; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARRIER PROTEINS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 43549092061     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0207     Document Type: Article

References (26)